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end of 2007 and linked with the National mortality database. Kaplan–Meier method
was used to yield the estimated survival function of both groups. Constant excess 
hazard model was used to project the long-term survival of these patients by utilizing 
linear extrapolation. Life expectancy was estimated while EYLL was calculated by
subtracting the life expectancy of patients from those of their age- and gender-matched
referents. HD patients were then matched with PD patients on age, gender, and dia-
betic status. Life expectancy, EYLL and survival for the two groups were re-compared. 
Cox Model was applied to determine the risks for mortality. RESULTS: A total of 
305 HD and 428 PD patients were included. Before matching, HD patients were older 
than PD patients (62.4 o 13.7 versus 53.1 o 16.7 years, p  0.0001), and more HD 
patients had diabetes mellitus (DM) (HD versus PD, 29.2% versus 20.6%, p 
0.0072). Life expectancy and EYLL of HD patients were 8.8 and 11.5 years, compared
with those of PD patients (19.9 and 7.4 years). After matching, 236 pairs of HD and
PD patients were selected. Life expectancy (p  0.790) and EYLL (p  0.793) of both 
groups were similar on re-analysis. Age (adjusted hazard ratio, AHR 1.07, 95% CI 
1.05–1.09) and DM (AHR 3.81, 95% CI 2.28–6.36) were independent predictors of 
mortality. For diabetic patients, survival was better if the patients were treated with 
HD (AHR 0.24, 95% CI 0.11–0.53). CONCLUSIONS: After matching, life expec-
tancy and EYLL between HD and PD patients were similar, but survival was better
for diabetic patients if they were treated with HD.
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OBJECTIVES: To determine the proportion of OAB patients potentially at risk for
adverse events by assessing CV co-morbidity as measured during the six months prior 
to OAB diagnosis/treatment by biologic measures, CV diagnoses, and CV concomitant 
drug use among treated and untreated OAB patients. METHODS: The GE Centricity 
EMR database was utilized to identify patients with a diagnosis of OAB using ICD-9 
codes or a prescription between January 1, 1996 to March 30, 2007 for an OAB
antimuscarinic agent. The treated OAB patients with 13 months of continuous eligibil-
ity pre- and post-index date formed the OAB cohort. Based on the presence of q1 
pharmacy claim for an OAB antimuscarinic agent, the OAB cohort was stratiﬁ ed as
treated or untreated. A random sample of age and gender matched patients formed a 
comprehensive non-OAB control cohort; they had no diagnosis of OAB, urinary 
bladder dysfunction, or pharmacy claim for an OAB antimuscarinic agent. RESULTS:
OAB patients (N: 41,440; 83.6% women; median age 65 years), when compared to
non-OAB patients (N: 77,272; 83.2% women; median age 64 years), were more likely 
to have CV comorbidities (57.6% vs. 44.6%; p  0.001), a high heart rate (q80 beats 
/ minute) (31.4% vs. 19.9%; p  0.001), higher Framingham risk (9.9% vs. 9.6%; p 
 0.005) as well as use of CV medications (57.1% vs. 38.8%; p  0.001). In treated 
vs. untreated OAB patients, CV comorbidities (58.8% vs. 53.7%; p  0.001), propor-
tion with a high heart rate (32.3% vs. 27.6%; p  0.001) and Framingham risk (10.2% 
vs. 8.6%; p  0.001) and use of CV medications (60.7% vs. 42.4%; p  0.001) also
differed. CONCLUSIONS: CV comorbidities were more prevalent in OAB patients 
than in patients without OAB. Among the OAB patients, CV co-morbidity and prior 
exposure to CV medications was more prevalent in those who received antimuscarinic
treatment than in patient who did not receive treatment.
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OBJECTIVES: This study evaluates the difference in total hospital charges and length
of stay (LOS) between peritoneal dialysis (PD) and hemodialysis (HD) patients.
METHODS: Hospital inpatient data was analyzed from the Healthcare Cost and 
Utilization Project’s 2006 National Inpatient Sample. Patients were identiﬁ ed as HD 
or PD by a procedure code of 39.95 or 54.98, respectively, and a diagnosis code for 
end-stage renal disease (585.6). Exclusion criteria include having a procedure code for 
both PD and HD, a diagnosis code for acute renal failure (584.x), or under age 18. 
Differences in LOS and total charges were analyzed using univariate and multivariate
analysis adjusted for age, gender, and comorbidities. Subgroup analyses were done by 
payer type. RESULTS: 530,409 HD and 22,031 PD discharges met inclusion and 
exclusion criteria. PD patients were younger, more female, and had less comorbidity. 
The mean total charge for a PD discharge was $35,846 compared to $41,336 for HD 
(p  0.0001). The mean LOS was 6.57 days for PD and 7.25 days for HD (p  0.0001).
After adjusting for covariates, HD total charges were 13.9% higher than PD (p 
0.0001) and LOS was 6.7% longer (p  0.0086). For Medicare patients, total charges 
were 10.0% higher in HD patients (p  0.0001) and LOS was not different between 
HD and PD. For patients with private insurance, mean total charges were 21.7%
higher in HD patients (p  0.0001) and LOS was 9.2% greater (p  0.01). The charge
difference, HD minus PD, between private and Medicare patients was signiﬁ cantly
higher in the former. CONCLUSIONS: Adjusted mean total charges and LOS were 
signiﬁ cantly higher in patients receiving HD compared to PD. LOS was signiﬁ cantly 
longer in privately insured HD patients but not in Medicare HD patients. The charge 
difference between HD and PD was signiﬁ cantly higher in privately insured compared 
to Medicare patients.
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OBJECTIVES: The objective of this study was to determine the cost effectiveness of 
paricalcitol versus standard treatment in patients with chronic kidney disease (CKD)
in the health care setting in Italy, Portugal and Turkey in 2008. METHODS: A Markov 
process model was developed employing data sources from the published literature,
paricalcitol clinical trials, ofﬁ cial country price/tariff lists and national population 
statistics. The comparator was the standard treatment for each country; Italy, Portugal,
and Turkey. The primary perspective of the study was that of the society. The primary 
efﬁ cacy outcome in the Paricalcitol (reduction SHPT, reduction proteinuria, complica-
tions and mortality) were extrapolated to effectiveness outcomes: number of life years 
gained (LYG) and number of quality-adjusted life-years (QALYs). Clinical and eco-
nomic outcomes were discounted at 3.0%. RESULTS: The base case analysis is based
on a 10-years time horizon and a comparison of paricalcitol in stage CKD 3, CKD 4 
and CKD 5 versus standard treatment. The use of paricalcitol leads to an additional
medical cost of €4335 to €6564; and an increase in life years gained of 0.48 to 0.67
years, and a gain in QALYs of 0.42 to 0.64. Consequently the use of paricalcitol results
in an ICER of less than €11,000/QALY from the perspective of the society in all three 
countries. This value is well below the willingness to pay threshold. CONCLUSIONS:
The results showed that the favorable clinical beneﬁ t of paricalcitol results in positive 
short and long-term health economic beneﬁ ts. This study suggests that the use of 
paricalcitol in patients with early chronic kidney disease may be cost-effective from a 
society perspective in Italy, Portugal and Turkey.
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OBJECTIVES: A 12 week clinical trial (TIMES) demonstrated that therapy with 
tolterodine extended release (TOL)  tamsulosin (TAM) provides clinical beneﬁ ts 
versus TOL or TAM monotherapy or placebo (PBO) in men with lower urinary tract 
symptoms (LUTS) including overactive bladder (OAB). The present analysis estimated 
the costs and quality adjusted life years (QALYs) associated with these therapies from 
the perspective of the UK health care system. METHODS: TIMES cohorts receiving 
TOL, TAM, TOLTAM, or PBO were followed from therapy initiation to 12 weeks. 
A decision tree model was used to extrapolate the 12-week results to 1 year (including
need for surgery owing to treatment failure at 12 weeks), and to track patients’ out-
comes (symptoms, utility, and costs). Because TIMES did not include costs and 
QALYs, data from the EpiLUTS epidemiologic survey (9416 males) were used to 
model a mathematical relationship between LUTS (daytime and nocturnal frequency, 
urgency episodes, urgency urinary incontinence episodes, and International Prostate 
Symptom Scores [IPSS]), quality of life, and utility. This was used to convert improve-
ments in TIMES patients’ LUTS into utility scores and QALYs. The model included 
drug and surgery procedure costs and hospital length of stay. RESULTS: Incremental
QALYs of TOLTAM vs PBO, TAM and TOL were 0.033, 0.016 and 0.011, and
corresponding incremental costs were a262, a253 and -a30, respectively, resulting in 
cost-utility ratios for TOLTAM of a7,894/QALY gained compared with PBO, and 
a15,346/QALY gained compared with TAM. TOLTAM combination therapy was 
both more effective and cost-saving compared with TOL. Univariate sensitivity analy-
ses showed that patient utility was most responsive to changes in IPSS score and
number of urgency episodes. Changing the percentage of patients undergoing surgery 
did not substantially affect model outcomes. CONCLUSIONS: The TOLTAM com-
bination therapy appears to be cost-effective compared with TOL or TAM mono-
therapy or PBO in male patients with LUTS.
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OBJECTIVES: The calcineurin inhibitor (CNI) regimens, including tacrolimus or
cyclosporine, have improved the overall success of renal transplantation through 
increased short-term patient and graft survival. However, this has not translated into
